Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm multi-cohort study of sacituzumab govitecan in advanced solid tumors
CTR20210912Phase 2Active
- Sponsor
- Everest Medicines
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, Cervical Cancer (CC), biliary cancer, Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Everest Medicines. Started Oct 2021; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomaCervical Cancer (CC)biliary cancerNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20210912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210912.